VOLUME 8 NUMBER 3 • SEPTEMBER 2011
131
SA JOURNAL OF DIABETES & VASCULAR DISEASE
ADA WATCH
target in order to reduce complications
of type 1 diabetes [Abstract 0080-OR].
Higher vitamin D status is associated
•
with a lower risk of diabetes in the Dia-
betes Prevention Program (DPP) [Abstract
0117-OR].
Lifestyle changes and metformin therapy
•
reduce the biomarkers of inflamma-
tion, endothelial function and coagula-
tion but these effects are influenced by
age, gender and ethnicity [Abstract
0119-OR].
Flaxseed, a good source of omega-3
•
fatty acids and viscous fibre, decreases
glucose and improves glycaemic control
in individuals with pre-diabetes, accord-
ing to a randomised, controlled study
[Abstract 0122-OR].
The Diabetes Prevention Trial – Type 1
•
Risk Score (DPTRS) is useful for identify-
ing normoglycaemic children at high risk
of developing type 1 diabetes [Abstract
0158-OR].
Diffusion tensor imaging (DTI) has
•
shown changes in the structure of the
white matter of the brain in young
children with type 1 diabetes [Abstract
0162-OR].
Fenofibrate-induced impairment in renal
•
function seen in the ACCORD trial of
type 2 diabetes patients is reversible
after 50 days off the drug [Abstract
0368-OR].
Analysis of the five-year data from the
•
ACCORD trial shows that exposure
to any insulin was not associated with
increased risk of cancer-related out-
comes. This is hypothesis-generating
data [Abstract 0365-OR].
Higher baseline 25(OH)D vitamin D
•
independently predicted better beta-
cell function and lower area-under-the-
curve (AUC) glucose in patients at higher
risk of developing diabetes [Abstract
0325-OR].
Novo Nordisk (Pty) Ltd. Reg. No.: 1959/000833/07. PO Box 783155, Sandton, 2146. Tel: (011) 202 0500 Fax: (011) 807 7989 NN/DUO/4145/07/10/VER1
